On April 4, 2014 Halozyme Therapeutics announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202/NCT01839487) evaluating PEGPH20 in patients with pancreatic cancer (Press release Halozyme, APR 4, 2014, View Source [SID:1234500367]). The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20. The Company is halting enrollment and dosing of PEGPH20 as precautionary actions while the DMC’s full evaluation of the data is ongoing.